InnaMed

Using at-home blood testing technology to enable personalized medicine

Analytics

Raised to Date: Raised: $1,281,106

Aggregate Commitments $
Platform

Wefunder

Start Date

06/10/2021

Close Date

06/16/2021

Min. Goal

$100,000

Max. Goal

$3,930,000

Min. Investment

$100

Security Type

SAFE

Funding Type

RegCF

Series

Series A

Valuation Cap

$25,000,000

Discount Rate

0%

Rolling Commitments $
Status
Funded
Reporting Date

06/30/2021

Days Remaining
Funded
% of Min. Goal

1,281%

% of Max. Goal

33%

Likelihood of Max
Funded
Avg. Daily Raise

$213,518

# of Investors

1,407

Momentum
Funded
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

Philadelphia, Pennsylvania

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

High

Capital Intensity

High

Business Type

High Growth

InnaMed, with a valuation cap of $25 million, is raising crowdfunding on Wefunder. The company is developing an at-home testing device called TeleLab. The device can be filled with several disease-specific test cartridges and helps to monitor the patients remotely. InnaMed is using modern blood collection techniques, cloud computing, and its patented electrochemical blood analysis technology to provide lab-level testing at home. The company was founded by Eshwar Inapuri, Alan Jernigan, and Anup Singh in May 2016 and has raised over $2 million in previous rounds of financing. The proceeds of the crowdfunding round, with a minimum target of $100,000 and a maximum target of $1,070,000, will be used for research and development materials and contractors, payroll, marketing, and facilities. InnaMed generated more than $1.4 million in revenue in 2020 through its multi-year collaborations.
Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$1,439,995

$237,435

COGS

$0

$0

Tax

$1,638

$808

 

 

Net Income

$-212,485

$-474,753

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$572,704

$844,551

Accounts Receivable

$150,000

$0

Total Assets

$914,741

$882,560

Short-Term Debt

$196,705

$3,426

Long-Term Debt

$30,000

$0

Total Liabilities

$226,705

$3,426

Financials as of: 06/10/2021
Log in or create a free account today to gain access to KingsCrowd analytics.
Raise History
Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
InnaMed 06/16/2021 Wefunder $25,000,000 $1,281,106 SAFE Funded RegCF
InnaMed 07/31/2019 Republic $12,000,000 $1,070,000 SAFE Funded RegCF
Log in or create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Staff Picks (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including Merlin ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by Merlin ratings
Company specific Merlin rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Ratings

Analyst Report

Synopsis

Modern medical science is becoming increasingly personalized. Genetic analysis can tell us all about our ancestral history. Tools like thermometers and scales track our health more effectively than ever with smart technology. Perhaps most significantly, analysis of blood detects chemical imbalances in our bodies, verifies pregnancies, manages diabetes, and tracks disease, among other things.

Unfortunately, collecting these samples presents a huge bottleneck in providing needed treatment. The process is logistically intensive, requiring physician’s orders, collection at a designated site, and proper handling. In addition, patient noncompliance with required testing and treatment is discouragingly prevalent.

What if patients didn’t have to go through the rigorous process of traditional blood collection and testing? InnaMed is answering that question with an at-home testing system. Patients will be able to use one-time collection tools and analysis cartridges to collect blood and conduct analysis, essentially condensing the entire blood collection system into a box that can fit on a countertop. Results are available within minutes, in some cases, and patients can report symptoms to effectively and comprehensively optimize treatment plans.

While the product has not yet been fully developed and will require FDA approval, InnaMed has secured an assortment of patents and publications to smooth the way to market dominance. Eventually, InnaMed hopes to significantly streamline the patient monitoring process, saving money, improving compliance, and easing the burden on patients.

InnaMed’s current Wefunder raise has been rated a Top Deal by the KingsCrowd investment team.

Price

To conduct further research and finance materials, contractors, payroll, marketing, and facilities InnaMed is raising through a Crowd SAFE at a valuation cap of $25 million with no discount. This is more than double the company’s $12 million valuation when it raised on Republic in 2019. While the valuation is quite high for a company still developing its product, its revenue is significant and growing (up five times from 2019), and we give InnaMed a middle-of-the-road price rating.

Market

The blood testing market is significant, though it isn’t huge. The North American blood testing market was estimated at $19.45 billion in 2020, and is growing at a CAGR of 2.32%, predicted to be worth $21.82 billion in 2025. The global market is much larger and is expanding significantly faster, at a CAGR of 6.6%; however, the real question is just how quickly this traditionally out-of-home industry will migrate to at-home testing. Greater acceptance of telehealth is leading to increased emphasis on such options throughout the healthcare industry.

We should also note that InnaMed’s product will be able to replace virtually the entire blood screening process, so its total addressable market is closer to the entire market size than other startups that account for only a small share of their respective industries. As the pandemic begins to draw to a close, InnaMed has smartly pivoted to a B2B model, working with pharmacies directly on development and ensuring a product-market fit.

Team

InnaMed’s leadership team is largely young, but holds sufficient relevant experience. CEO and co-founder Eshwar Inapuri holds a Bachelor’s Degree in Bioengineering from The University of Pennsylvania, and has been working to build up his experience throughout his education. He started with therapy R&D while still in high school, spent some time working in finance for Clark Hill PLC, and spent three years working on point-of-care diagnostics research at UPenn while developing InnaMed. While he’s fresh out of college, he has already picked up some level of practical work experience and has had his findings published in a peer-reviewed journal, PNAS.

CSO and co-founder Anup Singh is slightly more experienced. He holds a Master of Science in Physics, also from UPenn, and is putting his PhD in Bioengineering at UCLA on hold while he works on InnaMed. Like his co-founder, he has spent a number of years in research working with microfluidic technologies. 

Likely to make up for the pair’s somewhat limited work experience, they recently brought on board Commercial Development Lead Tom Larson. Larson is a twenty-five-year veteran of the pharmaceutical and healthcare industries. After working more than a decade in various sales and marketing roles with Abbott, Larson joined Johnson & Johnson and a series of pharmaceutical companies of varying sizes; most recently, he served as Senior VP and CCO at Ascendis Pharma, an experimental/innovative biotech company. These experiences place him in an apt position to help guide the evolution of InnaMed.

Differentiators

When it comes to setting itself apart from the competition, InnaMed is unmatched. The market is beginning to fill up with products that can complete the blood collection process at home, but there is a notable absence of products that can also complete the testing process and provide results almost immediately. On that front, InnaMed has taken the lead, and it is taking all the requisite steps to ensure the defensibility of its product with a broad assortment of 9 patents and 5 peer-reviewed publications on its tech. Potential competitors have a long way to go before they can pose a threat to InnaMed.

Performance

As with InnaMed’s differentiation score, there is much to admire about this startup’s early performance. The company remains pre-profit, but has seen stellar revenue growth, especially in the past year which saw $1.44 million in revenue (a 5x increase over 2019). In large part, this is due to interested clinical parties financing R&D and pre-ordering specific testing cartridge units. InnaMed has also successfully raised funds on Republic, demonstrating a capacity for marketing and financial savvy; this has kept outstanding debts low at less than a quarter-million dollars.

Bearish Outlook

While InnaMed’s early success and strong differentiation promise a bright and lucrative future for the company, it is still technically pre-product; all of its early funding has come through R&D funding, pre-orders, and a prior successful raise. Though the technology holds significant promise and could be a game-changer for providers and patients alike, it will need to prove product safety, efficacy, and accuracy before it can begin replacing on-site blood testing at scale. The product has a long way to go before it can be mass-produced and start providing the large-scale, recurring revenue it has the potential for.

Bullish Outlook

Though InnaMed isn’t yet ready to show significant returns, it is clearing potential roadblocks along the way. It is securing extensive product protection through patents, and engaging future customers along the development process. While it will need to clear regulatory hurdles with the FDA before production, potential investors will be pleased to know the process is unlikely to take more than a year to a year-and-a-half, which lowers risk. InnaMed is in a very good position to become dominant in a multi-billion dollar industry, and as of yet, its competition has not caught up to what it is offering. At the very least, a potential acquisition somewhere down the line cannot be ruled out, as big players in the healthcare industry are likely to want to corner the at-home blood testing market as quickly as possible. The company does not appear to be headed for an exit, but even without one, they are being financially and technologically smart and could begin to see significant returns for investors in just a few years.

Executive Summary

InnaMed is a biotechnology company developing HomeLab, an at-home blood testing device. The device has three parts: a disposable collector, disposable analyzer, and a countertop Internet of Things device to read and transmit results. Once developed and approved, the product will be able to replace the harrowing process of blood testing that is currently the norm.

While InnaMed’s leadership team is extremely young — mostly fresh out of the University of Pennsylvania — they have seen massive revenue growth and secured strong patent protections for their product. A lack of any comparable competitors and a growing at-home diagnostics market promise a lucrative future for this startup. A somewhat high valuation is the only dim spot in what is otherwise an extremely attractive investment opportunity. For these reasons, the KingsCrowd investment team gave InnaMed a Top Deal rating.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to support@kingscrowd.com.

Analysis written by Benjamin Potts.

Other Deals

Cheers on StartEngine

Alcohol consumption is one of the oldest human practices on record. A study released in…

RegCF
EnGen Bio on Wefunder

COVID-19 has brought the world’s attention to vaccine development. In April 2021, a record 4

RegCF
Audubon Bioscience on MicroVentures

In 2020 alone, companies produced, tested, and began to produce a vaccine for a completely new virus on…

RegCF
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add InnaMed on Wefunder
Follow company
Follow InnaMed on Wefunder
Want to learn more about InnaMed?
Join the Pre-IPO Market’s #1 Ratings & Analytics Service FREE for 7 days.
Yes! I want to start my free trial.
Already a member? Log in here.